MedEx answers any queries you might have regarding Gleevec-100 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Indications for application of Gleevec 100 mg.
The well-studied effect of the cytostatic agent Gleevec 100 mg allows one to prescribe it for different forms of blood cancer and oncopathologies occurring in the gastrointestinal tract. The choice of treatment tactics (monotherapy or combinatorial) depends on the clinical picture of the pathology and the appropriateness of using this particular remedy (gene changes in cancer cells). It can be prescribed to children who have been diagnosed with chronic myeloid leukemia, but there are no data on other oncopathologies confirming the possibility of safe use for a child’s organism.
Chronic myeloid leukemia: if first detected in the patient, in phases of blast crisis or acceleration, and even during the chronic phase.
Acute lymphoblastic leukemia: if the patient has been diagnosed for the first time, with relapses, or refractory. Applicable if ALL is positive for a chromosomal trait (a modified Philadelphia chromosome).
Oncological diseases, caused by gene disorders of the receptors, which are responsible for the factors affecting the growth of platelets (forms of the disease: myelodysplastic or myeloproliferative).
Systemic mastocytosis, which has a certain status of mutational changes.
Eosinophilic leukemia (chronic), as well as hypereosinophilic syndrome.
Malignant stromal tumors of the gastrointestinal tract (inoperable stages or oncology of metastatic origin).
Dermatofibrosarcoma (inoperable, as well as with metastatic or recurrent stages).
Important: Dosage and treatment regimen (mono- or combination therapy) is selected by an experienced specialized oncologist, in accordance with the results of the refining diagnosis, which results in the decision on the expediency of using this particular medicine.
Contraindications of Gleevec 100 mg.
Individual hypersensitivity (intolerance) of the main substance (Imatinib) or other components of the components.
Children of the age category up to two years (there is no data on effectiveness, and, most importantly, safety).
During pregnancy and during breast-feeding.
Hepatic failure (acute).
Systemic impairment of kidney function.
Cardiovascular diseases (especially associated with the risk of manifestations of heart failure or if there is a regular need for patients to undergo hemodialysis).
Possible adverse effects of Gleevec 100 mg.
Since Gleevec 100 mg (Imatinib) has been used in medical practice for a long time, various negative reactions of the patient’s body have been well studied. This helps doctors to monitor not only the effectiveness of therapy in each specific case, but also determine the appropriateness of its application in the future. And also the opportunity to change the remedy or interrupt the course of treatment, if there are sufficient grounds. An analysis of the incidence of adverse reactions has made it possible to compile a statistical table in which “very often” refers to 1 out of 10 patients undergoing treatment, “sometimes” means 1 in a thousand, and “rarely” in 1 out of 10,000 cases.